In September of this year, Shanghai International Biopharma Industry Week and London Life Sciences Week launched a strategic partnership.
On Monday local time (the 16th), the third London Life Sciences Week officially kicked off.
London Mayor Sadiq Khan announced at the opening ceremony that 22 million pounds would be allocated from the funding distributed to London under the "Local Innovation Partnership Fund" to support three projects in the life sciences and quantum technology fields.
He stated that London should not only become Europe's life sciences capital, but also the world's life sciences capital.
On the same morning, the second China-UK Health Innovation Dialogue was held in London.
John Edwards, Investment Director at the UK Office for Investment, and Tang Song, Deputy Director-General of the Investment Promotion Agency of China's Ministry of Commerce, delivered speeches respectively, and representatives from more than ten Chinese and British companies and institutions spoke in succession.
The meeting also introduced the progress of the UK-China Health Innovation Platform (UKCHIP) and the work plan of the Silver Economy Working Group.
London's Strengths and Weaknesses
London & Partners, citing Dealroom data, said that since the beginning of this year, London life sciences companies have secured 2.5 billion pounds in venture capital, 40% higher than the 1.8 billion pounds for all of 2025.
Since 2015, London has produced 13 life sciences unicorn companies, the highest number among European cities.
Artificial intelligence (AI) is another calling card.
In 2025, London's AI biotechnology sector attracted about 750 million pounds in investment, second only to Boston.
Isomorphic Labs, an AI drug discovery company headquartered in London and spun out of Google DeepMind, completed a $2.1 billion Series B financing round in May this year.
To accommodate growth, London is expanding its infrastructure.
According to data from commercial real estate services firm CBRE Group Inc (CBRE), London currently has about 1.6 million square feet of laboratory and R&D space, with another 31 projects under construction that will add 6.6 million square feet.
However, London & Partners also acknowledged in its report that while London can cultivate valuable companies, the next challenge is helping more companies scale up, which requires more late-stage venture capital as well as faster regulatory approvals and adoption by the UK National Health Service (NHS).
In addition, NHS London has launched a life sciences strategy, planning to introduce an "innovator passport," as well as a regulatory sandbox by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AI medical devices.
This year, the average start-up time for UK commercial clinical trials has been shortened to 100 days.
These Barriers Remain in Two-Way Exchange
In London's process of building itself into the world's life sciences capital, China is an unavoidable topic.
At the second China-UK Health Innovation Dialogue, Rahul Agarwal, Counsellor for Life Sciences and Healthcare at the Department for Business and Trade of the British Embassy in China, said: "In translational medicine and translational research, the UK can serve as a springboard for Chinese companies."
Agarwal said that many Chinese original research drugs can go through the MHRA's fast-track approval channel and conduct Phase II and Phase III clinical trials.
Flow in the opposite direction is also happening.
Agarwal said that some British biotechnology companies, especially smaller ones, are turning to China for R&D and clinical trials, mainly attracted by lower costs, faster speed, and larger scale.
The UK government will guide these companies to value intellectual property protection, understand regulatory thresholds, and introduce partners to them.
James Caseley, Chief Commercial Officer of British nutritional supplement company Parkacre, told reporters that the company has been doing business with China for nearly 20 years, and the attraction is "scale."
In September of this year, Shanghai International Biopharma Industry Week and London Life Sciences Week launched a strategic partnership.
Agarwal believes that London is Europe's financial center, and most global life sciences companies set up their China headquarters in Shanghai, adding, "I hope to see more exchanges between the two sides."
Chinese companies' enthusiasm for the UK market is also heating up.
Several attending company representatives told reporters that more people were sent to attend this year than last year.
Zhi Yuan, Chairman of Baoyu Mingzhi Medical Device Service Group, is a "repeat visitor," having attended once last year and returning again this year, hoping to promote the real implementation of Chinese medical device projects in the UK.
But Chinese companies coming to the UK must also cross thresholds.
After listening to the remarks by British institutions at the meeting, Zhi Yuan summarized them as "three hurdles": first, passing the drug regulatory authority's approval for safety and efficacy; second, passing NICE's health economics evaluation; and finally, passing the NHS procurement review.
In his view, Chinese companies should not wait until their products complete domestic registration before considering the UK market, but should consider the characteristics of UK patients, the diagnosis and treatment environment, and health economics requirements at the project initiation stage, so that "such products can truly meet the needs of both markets."
Comments